ArriVent BioPharma, Inc. (NASDAQ:AVBP) to Post Q1 2024 Earnings of ($1.25) Per Share, HC Wainwright Forecasts

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for ArriVent BioPharma in a research report issued on Tuesday, April 30th. HC Wainwright analyst R. Burns forecasts that the company will earn ($1.25) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.16) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2024 earnings at ($0.64) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($3.03) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.09) EPS.

A number of other equities analysts have also recently commented on the stock. The Goldman Sachs Group started coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They issued a “buy” rating and a $27.00 target price on the stock. Citigroup began coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $30.00 target price for the company. Finally, Jefferies Financial Group started coverage on ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $35.00 price target on the stock.

ArriVent BioPharma Price Performance

AVBP stock opened at $16.69 on Thursday. ArriVent BioPharma has a one year low of $14.35 and a one year high of $25.95. The business has a 50 day moving average of $18.12.

Institutional Investors Weigh In On ArriVent BioPharma

An institutional investor recently bought a new position in ArriVent BioPharma stock. BNP Paribas Financial Markets bought a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,659 shares of the company’s stock, valued at approximately $83,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.